**Vibrio cholerae** Non-O1, Non-O139 Serogroups and Cholera-like Diarrhea, Kolkata, India


We identified 281 *Vibrio cholerae* non-O1, non-O139 strains from patients with diarrhea in Kolkata, India. Cholera-like diarrhea was the major symptom (66.0%); some patients (20.3%) had severe dehydration. These strains lacked the *ctxA* gene but many had *hlyA*, *rtxA*, and *rtxC* genes. Pulsed-field gel electrophoresis showed no genetic link among strains.

*Vibrio cholerae* O1 has been responsible for several cholera outbreaks in developing countries. During 1992, a novel serogroup, O139, caused cholera outbreaks in India and other countries in Asia (1). These events have shown that serogroups other than O1 have major epidemiologic roles in cholera. *V. cholerae* O1 and O139 serogroups produce cholera toxin (CT), a critical virulence factor and express toxin coregulated pilus (TCP), which are responsible for secretory diarrhea and intestinal colonization, respectively. Serogroups other than O1 and O139 are designated as *V. cholerae* non-O1, non-O139, or nonagglutinating vibrios (NAGs); such serogroups have >200 somatic (O) antigens (2) and mostly lack CT- and TCP-coding genes.

Toxigenic and nontoxigenic NAGs have caused several diarrhea outbreaks in India and other countries, including Haiti (3–6). In non–CT-producing NAGs, other virulence factors such as heat-stable enterotoxin (Stn), hemolysin (HlyA), repeat in toxin (RTX), and type 3 secretion systems (TTSS) have major roles in causing infections (7). In this study, we analyzed clinical characteristics of hospitalized patients with diarrhea infected with NAGs and screened strains for antimicrobial drug susceptibility, virulence genes, and genetic relatedness.

**The Study**

During 2002–2010, a total of 12,719 fecal specimens were collected, which represented every fifth hospitalized diarrhea patient at the Infectious Diseases Hospital in Kolkata and all children at the outpatient unit at B.C. Roy Memorial Hospital for Children in Kolkata. Fecal specimens were screened for *V. cholerae* and other enteric pathogens as described (8). NAGs were serotyped by using 206 polyclonal O antisera according to the protocol developed at the National Institute of Infectious Diseases (Tokyo, Japan) (2).

Antimicrobial drug susceptibility assays were performed by using the disk diffusion method and commercially available disks (Becton Dickinson, Sparks Glencoe, MD, USA), according to standards of the Clinical and Laboratory Standards Institute (9). Because these standards do not include interpretive criteria for *V. cholerae*, breakpoints for *Enterobacteriaceae* were adopted. *Escherichia coli* ATCC 25922 was used as a quality-control strain.

Simplex and multiplex PCRs were performed by using published methods specific for *ctxA*, *tcpA*, *rtxA*, *rtxC*, *stn*, and *hlyA* genes (classical/El Tor) and the TTSS-coding genes (7). Pulsed-field gel electrophoresis was performed according to the PulseNet standardized protocol for *V. cholerae* (www.pulsenetinternational.org/SiteCollectionDocuments/pfge/5.71_2009_PNetStandProtVcholerae.pdf). Gel Compare II software (Applied Maths NV, Sint-Martens-Latem, Belgium) was used for comparison of electrophoresis patterns. This software uses a Dice similarity index and contains an unweighted pair group with arithmetic mean method.

Of the 12,719 diarrhea feces specimens screened, 2,206 (17.3%) contained *V. cholerae*, which included *V. cholerae* O1 in 1,841 (83.4%), and O139 in 84 (3.8%). In the remaining 281 (12.7%) specimens, *V. cholerae* strains did not agglutinate with serogroups O1 or O139. This result was confirmed by species-specific *ompW* PCR, which included strains collected during 2003 (7). Among 281 strains, 175 (62.3%) NAGs were the only enteric pathogen found, and 106 (37.7%) of those NAGs were found with other enteric pathogens. The isolation frequency of NAGs ranged from 1.2% to 3.2% (Table 1).

1These authors contributed equally to this article.
Although *V. cholerae* O1 is highly prevalent in Kolkata, more NAGs were detected than in our previous study (10). A total of 224 (79.7%) strains were categorized into 80 serogroups; the remaining 57 (20.3%) were untypeable. Among typeable serogroups, 14 (6.2%) strains belonged to the O37 serogroup, and 11 (4.9%) each belonged to serogroups O6 and O34. Serogroups O97 (4.5%), O11 (3.6%), and O59 (3.1%) were also identified in this study. Although serogroups O11, O35, and O37 showed a lower prevalence, their prevalence was higher among patients with diarrhea in Kolkata (7,10). The prevalence rate of NAGs (≈2%) in Kolkata is similar to that in the Haizhu District of Guangzhou, China (11). However, the number of serogroups identified in China (26 serogroups) was less than in our study (80 serogroups).

Among age groups of patients, NAGs were detected mostly in patients >5 years of age (>72%) than in those <5 years of age (<28%) (Table 2). NAGs produce a spectrum of gastrointestinal symptoms ranging from asymptomatic infection to severe cholera-like illness or bloody diarrhea. In this study, most (70%) patients had watery diarrhea, which was similar to that for patients with cholera and those exclusively infected by NAGs (Table 2). Other clinical symptoms, such as dehydration status (22.3%) and fever (41.1%), were also high in patients with a single infection. In patients with mixed infections, bloody diarrhea (23.6%) and abdominal pain (41.5%) were the 2 major symptoms (Table 2), perhaps because >1 pathogen was involved.

Most NAGs were resistant to nalidixic acid (57.6%), ampicillin (55.5%), furazolidone (36.6%), and streptomycin (32.4%) and highly susceptible to gentamicin (96%), tetracycline (80%), and chloramphenicol (80.4%). During 1992–1997, antimicrobial drug resistance was high among *V. cholerae* isolated in Kolkata (12). In this study, patterns of antimicrobial drug resistance in NAGs were different than those in previous reports (10,12). This finding might be caused by discontinuation of ineffective antimicrobial drugs, such as co-trimoxazole and furazolidone, rational use of fluoroquinolones, and introduction of azithromycin for treating diarrhea.

### Table 1. Prevalence rates of *Vibrio cholerae* non-O1, non-O139 strains among patients with diarrhea, Kolkata, India

<table>
<thead>
<tr>
<th>Year</th>
<th>No. fecal specimens</th>
<th>No. (%) Strains isolated</th>
<th>Infection status</th>
<th>Single</th>
<th>Mixed</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>2,285</td>
<td>49 (2.1)</td>
<td></td>
<td>30</td>
<td>19</td>
</tr>
<tr>
<td>2003</td>
<td>1,673</td>
<td>53 (3.2)</td>
<td></td>
<td>29</td>
<td>24</td>
</tr>
<tr>
<td>2004</td>
<td>2,430</td>
<td>31 (1.3)</td>
<td></td>
<td>16</td>
<td>15</td>
</tr>
<tr>
<td>2005</td>
<td>1,472</td>
<td>38 (2.6)</td>
<td></td>
<td>27</td>
<td>11</td>
</tr>
<tr>
<td>2006</td>
<td>930</td>
<td>19 (2.0)</td>
<td></td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>2007</td>
<td>744</td>
<td>24 (3.2)</td>
<td></td>
<td>23</td>
<td>1</td>
</tr>
<tr>
<td>2008</td>
<td>1,124</td>
<td>35 (3.1)</td>
<td></td>
<td>22</td>
<td>13</td>
</tr>
<tr>
<td>2009</td>
<td>1,380</td>
<td>17 (1.2)</td>
<td></td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>2010</td>
<td>681</td>
<td>15 (2.2)</td>
<td></td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Total</td>
<td>12,719</td>
<td>281 (2.2)</td>
<td></td>
<td>175</td>
<td>106</td>
</tr>
</tbody>
</table>

### Table 2. Clinical characteristics of *Vibrio cholerae* non-O1, non-O139 strain–infected patients with diarrhea, Kolkata, India

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Infection status, no. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of diarrhea</strong></td>
<td>Single, n = 175</td>
</tr>
<tr>
<td>Watery</td>
<td>122 (70.0)</td>
</tr>
<tr>
<td>Loose with bloody mucus</td>
<td>30 (17.1)</td>
</tr>
<tr>
<td>Other</td>
<td>23 (13.1)</td>
</tr>
<tr>
<td><strong>Dehydration status</strong></td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>39 (22.3)</td>
</tr>
<tr>
<td>Moderate</td>
<td>136 (77.7)</td>
</tr>
<tr>
<td><strong>Age, y</strong></td>
<td></td>
</tr>
<tr>
<td>&gt;5</td>
<td>126 (72.0)</td>
</tr>
<tr>
<td>≤5</td>
<td>49 (28.0)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>106 (60.6)</td>
</tr>
<tr>
<td>F</td>
<td>69 (39.4)</td>
</tr>
<tr>
<td><strong>Fever</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>72 (41.1)</td>
</tr>
<tr>
<td>No</td>
<td>103 (58.9)</td>
</tr>
<tr>
<td><strong>Abdominal pain</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>69 (39.4)</td>
</tr>
<tr>
<td>No</td>
<td>106 (60.6)</td>
</tr>
</tbody>
</table>
there are several virulence factors in genetically distinct strains. On the basis of our results, current antimicrobial drug therapy in the clinical management of NAG-mediated diarrhea can be continued. Further epidemiologic studies are needed to determine the ecology, virulence factors, and public health role of NAGs.

This study was supported in part by the Japan Initiative for Global Research Network on Infectious Diseases, Ministry of Education, Culture, Sports, Science and Technology, Japan and from intramural grants of the Indian Council of Medical Research, New Delhi, India.

Ms Devarati Dutta is a doctoral candidate at the National Institute of Cholera and Enteric Diseases, Kolkata, India. Her main research interest is the pathogenesis and molecular biology of enteric vibrios.

References


Figure. *NotI* restriction patterns of genomic DNA of representative *Vibrio cholerae* non-O1, non-O139 strains, Kolkata, India. Dendrogram was generated by using the unweighted pair group with arithmetic mean method.


Address for correspondence: Thandavarayan Ramamurthy, National Institute of Cholera and Enteric Diseases, P-33, CIT Rd, Scheme XM, Beliaghata, Kolkata 700010, India; email: tramu@vsnl.net

For the latest EID podcasts, go to:
http://wwwnc.cdc.gov/eid/podcasts.htm